Financial News Commentary on VRTX - Vertex Pharmaceuticals, Incorporated

The Chief Executive of VRTX Was Discussed on The Call

Keeping up with a CEO is one way that we try to better understand the direction of a company, and there was talk about VRTX management on The Call.

As of this week's report, we have an Overvalued valuation on VRTX because the price has gotten too high to be justified by the fundamentals. When taking into account the amount of news coverage each stock normally sees as a percentage of the total, Vertex Pharmaceuticals, Incorporated has actually sunk a bit in comparison to the others. Our sentiment indicator, provided through the Motley Fool CAPS survey, suggests that investors are neutral overall towards VRTX and think that it will generally perform in-line with the S&P 500.

“… matt emmens chairman and ceo of VERTEX PHARMACEUTICALS. Thank you for joining us for the cnbc exclusive and I have a couple more coming up on "power lunch," larry, the ceos of ... …”

Analyst Opinion on VRTX the Topic for The Call

Analysts' opinions can often carry a lot of weight, especially when they make major news and are covered on The Call.

When taking into account the amount of news coverage each stock normally sees as a percentage of the total, Vertex Pharmaceuticals, Incorporated has actually sunk a bit in comparison to the others. As of this week's report, we have an Overvalued valuation on VRTX because the price has gotten too high to be justified by the fundamentals. Our sentiment indicator, provided through the Motley Fool CAPS survey, suggests that investors are neutral overall towards VRTX and think that it will generally perform in-line with the S&P 500.

“… Sam waxel, and that's ahead of VERTEX PHARMACEUTICALS doing its presentation here at j. P. Morgan later this morning. Needham & company is reiterating its buy rating on the ... …”

Vertex Pharmaceuticals, Incorporated (VRTX) Discussed on CNBC's Power Lunch

Vertex Pharmaceuticals, Incorporated is in the news. Find out how this impacts VRTX trading on Ockham Research.

>> fair enough. Mike ryan, thanks for the time. >>> you heard bertha saying earlier one of the best performers, shares of VERTEX PHARMACEUTICALS. Higher by 11%, $37.38. Cambridge massachusetts company unveg for positive test results on a drug to treat hepatitis c. Mike huckman joins us with vertex's ceo.

“… atitis c. Mike huckman joins us with vertex's ceo. …”

Vertex Pharmaceuticals, Incorporated (VRTX) Discussed on CNBC's Power Lunch

Vertex Pharmaceuticals, Incorporated is in the news. Find out how this impacts VRTX trading on Ockham Research.

Technologies is among the winners. There is the nasdaq which was the first to turn lower. >> bucking the trend VERTEX PHARMACEUTICALS a big winner on that stock has been up better than 12% company the company out with important data on its hepatitis c pill. The ceo joins us first on cnbc in just a moment. >> i'm michelle caruso-cabrera. Walmart, a dow component slashing prices further.

“… l. The ceo joins us first on cnbc in just a moment. >> i'm michelle caruso-cabrera. Walmart, a dow component slashing prices further. …”

Vertex Pharmaceuticals, Incorporated (VRTX) Discussed on CNBC's Power Lunch

Vertex Pharmaceuticals, Incorporated is in the news. Find out how this impacts VRTX trading on Ockham Research.

Fantastic numbers they put up. And some of these big drug stocks, of course, human genome. That's an amazing story. But there are others in the space as well. Vertex pharmaceutical, VRTX. I'd say that is the leadership area right now. It's not financials at all. They're not leading us down. They're just taking some of the air out of the financial balloon, although with my exposure, i'm in the faz, the double short financial, and i'm continue to trade soft. Let's switch gears here and talk about ford, which is topping the

“… at all. They're not leading us down. They're just taking some of the air out of the financial balloon, although with my exposure, i'm in the faz, the double short financial, and i'm continue to trade soft. Let's switch gears here and talk about ford, which is topping the …”

Vertex Pharmaceuticals, Incorporated (VRTX) Discussed on CNBC's Power Lunch

Vertex Pharmaceuticals, Incorporated is in the news. Find out how this impacts VRTX trading on Ockham Research.

>>> take a look at the stock of VERTEX PHARMACEUTICALS up better than 12%. Company out with a drug to treat hepatitis c. We'll talk to the ceo at 1:00 p.M. Eastern time first on cnbc. >>> stronger than expected economic data supporting the view that the economy is improving. Hence why we have a rally today on wall street.

“… conomy is improving. Hence why we have a rally today on wall street. …”

Vertex Pharmaceuticals, Incorporated (VRTX) Discussed on CNBC's Squawk On The Street

Vertex Pharmaceuticals, Incorporated is in the news. Find out how this impacts VRTX trading on Ockham Research.

Thank you very much. >>> up next, stock is up 13% since the bottom. And the company is one of jim cramer's favorites. Ceo of gold field joining us next live from johannesburg. >>> and later, the ceo of VERTEX PHARMACEUTICALS is sitting down with mike huckman about the hepatitis c drug. That's up 25% in the past three months.

“… man about the hepatitis c drug. That's up 25% in the past three months. …”

Vertex Pharmaceuticals, Incorporated (VRTX) Discussed on CNBC's Mad Money

Vertex Pharmaceuticals, Incorporated is in the news. Find out how this impacts VRTX trading on Ockham Research.

>> caller: one gigantic thank you for everything boo-yah! >> you are welcome for everything boo-yah right back at you, sunshine. >> caller: vertex. VRTX. >> I have so many great biotech companies that are completely and utterly thrown out the may I suggest that instead you

“… t that instead you …”